Nuveen
MLYS icon

Nuveen’s Mineralys Therapeutics MLYS Stock Holding History

Nuveen’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.42M Buy
274,843
+162,836
+145% +$4.47M ﹤0.01% 1880
2026
Q1 		$3.03M Sell
112,007
-10,940
-9% -$321K ﹤0.01% 2103
2025
Q4 		$4.46M Buy
122,947
+36,031
+41% +$1.44M ﹤0.01% 1959
2025
Q3 		$3.3M Buy
86,916
+9,269
+12% +$200K ﹤0.01% 2102
2025
Q2 		$1.05M Buy
77,647
+9,770
+14% +$142K ﹤0.01% 2581
2025
Q1 		$1.08M Hold
67,877
– – ﹤0.01% 2616
2024
Q4 		$836K Hold
67,877
– – ﹤0.01% 2786
2024
Q3 		$822K Buy
67,877
+1,248
+2% +$15.1K ﹤0.01% 2840
2024
Q2 		$780K Buy
66,629
+31,798
+91% +$400K ﹤0.01% 2839
2024
Q1 		$450K Hold
34,831
– – ﹤0.01% 3008
2023
Q4 		$300K Buy
34,831
+15,676
+82% +$123K ﹤0.01% 3147
2023
Q3 		$182K Hold
19,155
– – ﹤0.01% 3052
2023
Q2 		$327K Buy
19,155
+3,021
+19% +$45.2K ﹤0.01% 3002
2023
Q1 		$253K Buy
+16,134
New +$272K ﹤0.01% 2945

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen's MLYS Position: Q2 2026 in Review

Nuveen increased its Mineralys Therapeutics (MLYS) stake by 145% in Q2 2026, buying an estimated $4.47M and bringing the position to 274,843 shares worth $7.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

Nuveen first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Nuveen held 274,843 shares of Mineralys Therapeutics worth $7.42M as of Q2 2026.
  • Nuveen bought 162,836 Mineralys Therapeutics shares in Q2 2026, an estimated $4.47M.
  • Mineralys Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1880 holding.
  • Nuveen first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.